---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-017178"
form_type: "8-K"
ticker: "CGTX"
cik: "0001455365"
company_name: "COGNITION THERAPEUTICS INC"
filed_at: "2025-02-26T23:59:59+00:00"
generated_at: "2026-05-26T03:29:32.388128+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Cognition Therapeutics passes Phase 2 futility analysis for zervimesine in geographic atrophy

## Summary
- Oral zervimesine (CT1812) passed futility analysis in Phase 2 GA trial; treated patients experienced slower lesion growth vs placebo.
- MAGNIFY study enrolled 100 participants; final visits completed Feb 2025; full unblinded results expected Q2 2025.
- Company concluding study early to preserve capital; plans to pursue indications in Alzheimer's and DLB.
- Prior Phase 2 SHIMMER (DLB) showed 86% improvement on NPI; SHINE (Alzheimer's) showed 95% cognitive decline reduction in biomarker subgroup.

## SEC filing metadata
- accession: 0001104659-25-017178
- form_type: 8-K
- ticker: CGTX
- cik: 0001455365
- company_name: COGNITION THERAPEUTICS INC
- filed_at: 2025-02-26T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1455365/000110465925017178/0001104659-25-017178-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1455365/000110465925017178/tm257579d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-017178
- JSON: https://secwatch.observer/filing/0001104659-25-017178.json
- Plain text: https://secwatch.observer/filing/0001104659-25-017178.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.